XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Update

Posted by Casey Walker on Jul 28th, 2026

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totaling 36,172 shares, an increase of 286.4% from the June 30th total of 9,362 shares. Approximately 2.3% of the shares of the company are short sold. Based on an average trading volume of 57,229 shares, the short-interest ratio is currently 0.6 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, XTL Biopharmaceuticals currently has a consensus rating of “Sell”.

Read Our Latest Report on XTL Biopharmaceuticals

XTL Biopharmaceuticals Price Performance

NASDAQ XTLB opened at $2.81 on Tuesday. XTL Biopharmaceuticals has a 1 year low of $2.01 and a 1 year high of $10.28. The stock has a market capitalization of $6.19 million, a PE ratio of -4.40 and a beta of 1.45. The company’s 50 day simple moving average is $2.60 and its two-hundred day simple moving average is $2.87.

XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of ($0.26) million for the quarter.

About XTL Biopharmaceuticals

(Get Free Report)

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.